Scholl Verruca Removal System

Ülke: Malta

Dil: İngilizce

Kaynak: Medicines Authority

Aktif bileşen:

SALICYLIC ACID

Mevcut itibaren:

Scholl Consumer Products Limited 103 - 105 Bath Road Slough, SL1 3UK, United Kingdom

ATC kodu:

D11AF

INN (International Adı):

SALICYLIC ACID 40 % (W/W)

Farmasötik formu:

MEDICATED PLASTER

Kompozisyon:

SALICYLIC ACID 40 % (W/W)

Reçete türü:

OTC

Terapötik alanı:

OTHER DERMATOLOGICAL PREPARATIONS

Yetkilendirme durumu:

Suspended

Yetkilendirme tarihi:

2006-08-29

Bilgilendirme broşürü

 
LEAFLET 

Ürün özellikleri

Page 1 of 4 
SUMMARY OF PRODUCT CHARACTERISTICS 

1. 
TRADE NAME OF MEDICINAL PRODUCT 

Scholl Verruca Removal System 

2. 
QUALITATIVE AND QUANTITATIVE COMPOSITION 

Salicylic Acid 
40.0% w/w 

3. PHARMACEUTICAL 
FORM 

Plaster 

4. CLINICAL 
PARTICULARS 

4.1 THERAPEUTIC 
INDICATIONS 

For the treatment of common warts on the feet and hands. 

4.2  POSOLOGY AND METHOD OF ADMINISTRATION 

Adults and Children 
Select a medicated disc from those supplied which best fits the
size of the wart. 
Leave medicated disc in place on wart for 48 hours and repeat
treatment. 
Continue treatment for up to twelve weeks if necessary. 
No distinction is made between age groups.  

Neonates 
Neonates should not be treated. 

4.3 CONTRAINDICATIONS 

a) 
Not to be used by diabetics
or those with severe circulatory disorders, except following 
a doctors permission and recommendation. 
b) 
Not to be used if the skin around the wart is inflamed or broken. 
c) 
Not to be used on moles, birthmarks, warts with hair growing
from them, genital warts 
or warts on the face or mucous membranes.  

4.4  SPECIAL WARNINGS AND PRECAUTIONS FOR USE 

a) 
Discontinue use and remove dressing if excessive
discomfort or irritation is 
experienced. 
b) 
Do not apply to normal skin. 
c) 
For external use only. 

Page 2 of 4 
4.5  INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS
OF INTERACTION 

Not relevant to cutaneous use. 

4.6  PREGNANCY AND LACTATION 

Safety during pregnancy and lactation has not been established. 

4.7  EFFECTS ON ABILITY TO DRIVE AND USE MACHINES 

None stated. 

4.8 UNDESIRABLE 
EFFECTS 

Local irritation may occur. 

4.9 OVERDOSE 

None stated. 

5. PHARMACOLOGICAL 
PROPERTIES 

5.1 PHARMACODYNAMIC 
PROPERTIES 

Pharmacotherapeutic group 
Keratolytics 

Mechanism of Action 
The mechani